Form DEF 14A Vincerx Pharma Inc For: 8 May
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vincerx Pharma Inc (VINC)
Vincerx Pharma Inc stock price live, this page displays OTC VINC stock exchange data. View the VINC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vincerx Pharma Inc real time stock price chart below.
What Is the Vincerx Pharma Inc Stock Price Today?
The Vincerx Pharma Inc stock price today is 0.0127.
What Is the Stock Symbol for Vincerx Pharma Inc?
The stock symbol for Vincerx Pharma Inc is "VINC."
What Stock Exchange Does Vincerx Pharma Inc Trade On?
Vincerx Pharma Inc is listed and trades on the OTC Markets stock exchange.
Is Vincerx Pharma Inc a Good Stock to Buy?
Determining whether Vincerx Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VINC quote. (ISIN: US92731L3042)
What Is the Vincerx Pharma Inc Stock Price Today?
The Vincerx Pharma Inc stock price today is 0.0127.
What Is the Stock Symbol for Vincerx Pharma Inc?
The stock symbol for Vincerx Pharma Inc is "VINC."
What Stock Exchange Does Vincerx Pharma Inc Trade On?
Vincerx Pharma Inc is listed and trades on the OTC Markets stock exchange.
Is Vincerx Pharma Inc a Good Stock to Buy?
Determining whether Vincerx Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VINC quote. (ISIN: US92731L3042)
OTC Markets
Currency in USD
0.0127
0.0000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0127
0.0127
52 wk Range
0.0002
0.0740
VINC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.01270.0127
52 wk Range
0.00020.0740
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VINC Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a poor free cash flow yield
- Form PRE 14A Vincerx Pharma Inc For: 27 April
- Investing.com
Nasdaq to delist Vincerx Pharma by April 23- Investing.com
- Form DEF 14A Vincerx Pharma Inc For: 8 May
- Investing.com
- Form PRE 14A Vincerx Pharma Inc For: 27 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Earnings
Latest Release
May 15, 2025
EPS / Forecast
-1.40 / -0.12
Revenue / Forecast
-- / --
Compare VINC to Peers and Sector
Metrics to compare | VINC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVINCPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −2.4x | −0.4x | |
PEG Ratio | 0.00 | −0.16 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 9.2x | 3.0x | |
Upside (Analyst Target) | 0.0% | 156.7% | 48.7% | |
Fair Value Upside | Unlock | 8.3% | 5.6% | Unlock |
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vincerx Pharma (VINC) Stock Price Today?
The Vincerx Pharma stock price today is 0.0127 USD.
What Stock Exchange Does Vincerx Pharma Trade On?
Vincerx Pharma is listed and trades on the OTC Markets.
What Is the Stock Symbol for Vincerx Pharma?
The stock symbol for Vincerx Pharma is "VINC."
What Is the Vincerx Pharma Market Cap?
As of today, Vincerx Pharma market cap is 66.4700K USD.
What Is Vincerx Pharma's Earnings Per Share (TTM)?
The Vincerx Pharma EPS (TTM) is -8.9799.
From a Technical Analysis Perspective, Is VINC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Vincerx Pharma Stock Split?
Vincerx Pharma has split 1 times.
How Many Employees Does Vincerx Pharma Have?
Vincerx Pharma has 13 employees.
What is the current trading status of Vincerx Pharma (VINC)?
As of Aug 08, 2026, Vincerx Pharma (VINC) is trading at a price of 0.0127 USD, with a previous close of 0.0127 USD. The stock has fluctuated within a day range of 0.0127 USD to 0.0127 USD, while its 52-week range spans from 0.0002 USD to 0.0740 USD.
What Is the VINC After Hours Price?
VINC's last after hours stock price is 0.0128 USD, the stock has decreased by -0.0001, or -0.3900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.